Cargando…

Pasireotide treatment in Cushing’s disease: A single tertiary center’s experience

BACKGROUND/AIM: Cushing’s disease (CD), which cannot be controlled by surgery, requires medical treatment. In this situation, treatments with long-term effectiveness and safety profiles are needed. We aimed to evaluate the effects and adverse effects of pasireotide treatment in CD. MATERIALS AND MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	ŞAHİN, Serdar, KARİMOVA, Gular, ÖZCAN, Şeyda Gül, DURCAN, Emre, ÖZKAYA, Hande Mefkure, KADIOĞLU, Pınar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Scientific and Technological Research Council of Turkey (TUBITAK) 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381204/ https://www.ncbi.nlm.nih.gov/pubmed/36161631 http://dx.doi.org/10.3906/sag-2105-261

Ejemplares similares

Psychosocial effects and clinic reflections of the COVID-19 outbreak in patients with acromegaly and Cushing’s disease
por: Durcan, Emre, et al.
Publicado: (2021)

Is Metformin Use Associated With Decreased Thyroid Cancer Risk in Patients With Acromegaly?
por: Kadioglu, Pinar, et al.
Publicado: (2021)

MON-293 The Prevalence of Impulse Control Disorders in Patients with Acromegaly and Prolactinomas Treated with Dopamine Agonists
por: Ozkaya, Hande Mefkure, et al.
Publicado: (2020)

MON-269 FGFR-4 Expression in Pituitary Adenomas Is Associated with Aggressive Tumor Features
por: Kadioglu, Pinar, et al.
Publicado: (2020)

SUN-415 Is ‘’Visceral Adiposity Index’’ a Better Indicator of Metabolic Syndrome in Patients with Thyroid Nodules?
por: Durcan, Emre, et al.
Publicado: (2020)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
por: Feelders, Richard A., et al.
Publicado: (2023)

Clinical use of pasireotide for Cushing’s disease in adults
por: Ceccato, Filippo, et al.
Publicado: (2015)

Long‐term efficacy and safety of once‐monthly pasireotide in Cushing's disease: A Phase III extension study
por: Fleseriu, Maria, et al.
Publicado: (2019)

Life-Threatening Hypercalcemia due to Graves' Disease and Concomitant Adrenal Failure: A Case Report and Review of the Literature
por: Ozkaya, Hande Mefkure, et al.
Publicado: (2015)

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
por: Silverstein, Julie M.
Publicado: (2016)

Medical Therapy with Pasireotide in Recurrent Cushing’s Disease: Experience of Patients Treated for At Least 1 Year at a Single Center
por: Yedinak, Chris G., et al.
Publicado: (2017)

Monitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing's Disease
por: Yedinak, Chris, et al.
Publicado: (2013)

Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease
por: Machado, Márcio Carlos, et al.
Publicado: (2021)

Effectiveness of low-dose pasireotide in a patient with Cushing’s disease: antiproliferative effect and predictivity of a short pasireotide suppression test
por: Grossrubatscher, Erika, et al.
Publicado: (2015)

Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations
por: Colao, Annamaria, et al.
Publicado: (2013)

Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression
por: Mizuno, Tomoko, et al.
Publicado: (2021)

The treatment with pasireotide in Cushing’s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center
por: Simeoli, C., et al.
Publicado: (2019)

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”
por: Pivonello, Rosario, et al.
Publicado: (2019)

MON-680 Might Podocyturia Be an Early Marker for Diabetic Nephropathy in Males
por: Durcan, Emre, et al.
Publicado: (2020)

Effects of SGLT2 inhibitors on patients with diabetic kidney disease: A preliminary study on the basis of podocyturia
por: Durcan, Emre, et al.
Publicado: (2022)

Efficacy and safety of pasireotide for Cushing's disease: A protocol for systematic review and meta-analysis
por: Zhao, Nairui, et al.
Publicado: (2020)

Incretin Response to Mixed Meal Challenge in Active Cushing’s Disease and after Pasireotide Therapy
por: Barbot, Mattia, et al.
Publicado: (2022)

Successful Therapy Using Pasireotide Long-acting Release for Cushing's Disease Merged with Biochemical Acromegaly
por: Fukunaga, Kensaku, et al.
Publicado: (2020)

Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study
por: Boscaro, M., et al.
Publicado: (2013)

Cushing’s disease: Does low-dose pasireotide offer a comparable efficacy and safety to high-dose?
por: Wong, Mimi, et al.
Publicado: (2021)

Iatrogenic Cushing’s syndrome with inhaled steroid plus antidepressant drugs
por: Celik, Ozlem, et al.
Publicado: (2012)

A case of nodular posterior scleritis mimicking choroidal mass
por: Ozkaya, Abdullah, et al.
Publicado: (2015)

Screening for Cushing’s Syndrome in Obese Patients
por: Tiryakioglu, Ozay, et al.
Publicado: (2010)

Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study
por: Fleseriu, Maria, et al.
Publicado: (2019)

Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation
por: Stelmachowska-Banaś, Maria, et al.
Publicado: (2021)

Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: results from a Phase 3 study
por: Lacroix, André, et al.
Publicado: (2019)

Sustained hypercortisolemia after bilateral adrenalectomy in Cushing's disease
por: Muradov, Ilkin, et al.
Publicado: (2023)

LBODP091 The Reasons For Loss To Follow-up Of Patients With Gender Dysphoria
por: Kadioglu, Pinar, et al.
Publicado: (2022)

Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience
por: Gadelha, Mônica, et al.
Publicado: (2023)

MON-445 Long-Term Results of an Ongoing Non-Interventional, Real-World Observational Study of Pasireotide SC in Cushing's Disease
por: Yuen, Kevin, et al.
Publicado: (2019)

Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study
por: Findling, James W., et al.
Publicado: (2016)

Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
por: Petersenn, S., et al.
Publicado: (2017)

Pasireotide for the Medical Management of Feline Hypersomatotropism
por: Scudder, C.J., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_sal248b11kv2b41akb2bte0qge